No Country for Old Stents? Improving Long-term Patient Outcomes With Biodegradable Polymer Drug-eluting Stents

Robert A Byrne; Adnan Kastrati


Expert Rev Cardiovasc Ther. 2012;10(4):429-432. 

In This Article

Five-year View

The encouraging outcome data with biodegradable polymer DESs and the availability of high-quality platforms will result in an increased penetration of these stents into routine clinical practice over the next 5 years. In many catheterization laboratories, these stents will become workhorse devices. In parallel with this, the burden of dual antiplatelet therapy after stenting will probably be eased, with a reduction in the recommended minimum duration of therapy likely to occur 6 months after intervention, possibly guided by data acquired from surveillance high-resolution intravascular imaging. In the long term, the goal of technological development remains the adoption into routine usage – in broadly inclusive lesion types – of devices with not only biodegradable polymer coatings but also bioabsorbable backbones. However, despite ongoing iterative development, it is doubtful that this can be realized within 5 years.